VIR-2482 (Dose 1) for Flu

Phase 2

Waitlist Available

Research Sponsored by Vir Biotechnology, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 26 weeks

Summary

This trial is testing VIR-2482, a new treatment aimed at preventing the flu (influenza A). It focuses on healthy adults aged 18 to less than 65 years who do not have risk factors for serious flu complications. The treatment likely works by boosting the immune system or directly fighting the flu virus.

Eligible Conditions

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 26 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 26 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 26 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of Participants With Adverse Events of Special Interest (AESI)

Number of Participants With Clinical Laboratory Abnormalities

Number of Participants With Solicited Injection Site Reactions

+3 more

Secondary study objectives

Percentage of Participants With CDC-defined Influenza-like Illness (ILI) With Confirmed Influenza A (by Reverse Transcription Polymerase Chain Reaction [RT-PCR])

Percentage of Participants With WHO-defined Influenza-like Illness (ILI) With Confirmed Influenza A (by Reverse Transcription Polymerase Chain Reaction [RT-PCR])